These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 9761935)

  • 1. Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy.
    Canal P; Gamelin E; Vassal G; Robert J
    Pathol Oncol Res; 1998; 4(3):171-8. PubMed ID: 9761935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical treatment guide for dose individualisation in cancer chemotherapy.
    Canal P; Chatelut E; Guichard S
    Drugs; 1998 Dec; 56(6):1019-38. PubMed ID: 9878990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs.
    Rousseau A; Marquet P
    Fundam Clin Pharmacol; 2002 Aug; 16(4):253-62. PubMed ID: 12570013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptive control methods for the dose individualisation of anticancer agents.
    Rousseau A; Marquet P; Debord J; Sabot C; Lachâtre G
    Clin Pharmacokinet; 2000 Apr; 38(4):315-53. PubMed ID: 10803455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can pharmacokinetic and pharmacodynamic studies improve cancer chemotherapy?
    Newell DR
    Ann Oncol; 1994; 5 Suppl 4():9-14; discussion 15. PubMed ID: 8060901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma.
    Salas S; Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Tranchand B; Monjanel-Mouterde S; Baciuchka-Palmaro M; Dupuis C; Yang C; Balti M; Lacarelle B; Duffaud F; Durand A; Favre R
    Ther Drug Monit; 2006 Aug; 28(4):532-9. PubMed ID: 16885721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individual dose adaptation of anticancer drugs.
    Desoize B; Robert J
    Eur J Cancer; 1994; 30A(6):844-51. PubMed ID: 7917547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacokinetics and individual dose adjustment of carboplatin].
    Chatelut E; Canal P; Bugat R
    Bull Cancer; 2000 Aug; 87 Spec No():17-23. PubMed ID: 11082718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis.
    Stewart DJ; Raaphorst GP; Yau J; Beaubien AR
    Invest New Drugs; 1996; 14(2):115-30. PubMed ID: 8913832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [To which criterion should the dosage of anticancer drug be adapted?].
    Desoize B
    Bull Cancer; 1993 May; 80(5):376-90. PubMed ID: 8173191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.
    Paci A; Veal G; Bardin C; Levêque D; Widmer N; Beijnen J; Astier A; Chatelut E
    Eur J Cancer; 2014 Aug; 50(12):2010-9. PubMed ID: 24889915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
    Gerrits CJ; Schellens JH; Burris H; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Von Hoff DD; Verweij J
    Clin Cancer Res; 1999 Jan; 5(1):69-75. PubMed ID: 9918204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents.
    Chatelut E; White-Koning ML; Mathijssen RH; Puisset F; Baker SD; Sparreboom A
    Br J Cancer; 2012 Sep; 107(7):1100-6. PubMed ID: 22929884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
    Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
    Britten CD; Baker SD; Denis LJ; Johnson T; Drengler R; Siu LL; Duchin K; Kuhn J; Rowinsky EK
    Clin Cancer Res; 2000 Sep; 6(9):3459-68. PubMed ID: 10999729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.
    Zandvliet AS; Schellens JH; Beijnen JH; Huitema AD
    Clin Pharmacokinet; 2008; 47(8):487-513. PubMed ID: 18611060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
    Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
    Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
    Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ
    Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.